CoLucid Pharmaceuticals, Inc.
CLCD
CLCD was delisted on the 28th of February, 2017.
18 hedge funds and large institutions have $49.2M invested in CoLucid Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 18 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$26.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.9M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$4.81M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.72M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$916K |
Top Sellers
CLCD Hedge Fund Activity: Q2 2015 in Review
18 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in CoLucid Pharmaceuticals, Inc. (CLCD) for Q2 2015, worth a combined $49.2M.
Buyers outnumbered sellers: 18 funds opened new CLCD positions and 0 closed out — a net gain of 18 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $26.2M.
- 18 institutional investors held CoLucid Pharmaceuticals, Inc. (CLCD) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $49.2M of CoLucid Pharmaceuticals, Inc. stock for Q2 2015.
- 18 funds opened new CoLucid Pharmaceuticals, Inc. positions in Q2 2015 and 0 closed out, a net change of +18 holders.
- The largest CoLucid Pharmaceuticals, Inc. buyer in Q2 2015 was Novo Holdings A/S, an estimated $26.2M added.
Based on aggregated 13F filings for Q2 2015.